These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 30401535)

  • 1. Targeting PP2A in cancer: Combination therapies.
    Mazhar S; Taylor SE; Sangodkar J; Narla G
    Biochim Biophys Acta Mol Cell Res; 2019 Jan; 1866(1):51-63. PubMed ID: 30401535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of protein phosphatases in the cancer microenvironment.
    Ruvolo PP
    Biochim Biophys Acta Mol Cell Res; 2019 Jan; 1866(1):144-152. PubMed ID: 30026077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic targeting of PP2A.
    O'Connor CM; Perl A; Leonard D; Sangodkar J; Narla G
    Int J Biochem Cell Biol; 2018 Mar; 96():182-193. PubMed ID: 29107183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein phosphatase 2A regulatory subunits and cancer.
    Eichhorn PJ; Creyghton MP; Bernards R
    Biochim Biophys Acta; 2009 Jan; 1795(1):1-15. PubMed ID: 18588945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiologic functions of PP2A: Lessons from genetically modified mice.
    Reynhout S; Janssens V
    Biochim Biophys Acta Mol Cell Res; 2019 Jan; 1866(1):31-50. PubMed ID: 30030003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase.
    Sangodkar J; Farrington CC; McClinch K; Galsky MD; Kastrinsky DB; Narla G
    FEBS J; 2016 Mar; 283(6):1004-24. PubMed ID: 26507691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unraveling the complexity: A comprehensive analysis of the PP2A in cancer and its potential for novel targeted therapies.
    Ivovič D; Kabelíková P; Jurkovičová D
    Neoplasma; 2023 Aug; 70(4):485-499. PubMed ID: 37789785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional importance of PP2A regulatory subunit loss in breast cancer.
    Watt LF; Panicker N; Mannan A; Copeland B; Kahl RGS; Dun MD; Young B; Roselli S; Verrills NM
    Breast Cancer Res Treat; 2017 Nov; 166(1):117-131. PubMed ID: 28744751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The interaction of SET and protein phosphatase 2A as target for cancer therapy.
    Dacol EC; Wang S; Chen Y; Lepique AP
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188578. PubMed ID: 34116173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
    Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
    BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple pathways regulated by the tumor suppressor PP2A in transformation.
    Westermarck J; Hahn WC
    Trends Mol Med; 2008 Apr; 14(4):152-60. PubMed ID: 18329957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target.
    Khanna A; Pimanda JE; Westermarck J
    Cancer Res; 2013 Nov; 73(22):6548-53. PubMed ID: 24204027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer.
    Baumgartner U; Berger F; Hashemi Gheinani A; Burgener SS; Monastyrskaya K; Vassella E
    Mol Cancer; 2018 Feb; 17(1):44. PubMed ID: 29455644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A specific PP2A regulatory subunit, B56gamma, mediates DNA damage-induced dephosphorylation of p53 at Thr55.
    Li HH; Cai X; Shouse GP; Piluso LG; Liu X
    EMBO J; 2007 Jan; 26(2):402-11. PubMed ID: 17245430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. cAMP regulation of protein phosphatases PP1 and PP2A in brain.
    Leslie SN; Nairn AC
    Biochim Biophys Acta Mol Cell Res; 2019 Jan; 1866(1):64-73. PubMed ID: 30401536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PP2A subunit PR130 is a key regulator of cell development and oncogenic transformation.
    Dzulko M; Pons M; Henke A; Schneider G; Krämer OH
    Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188453. PubMed ID: 33068647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role and therapeutic potential of Ser/Thr phosphatase PP2A in apoptotic signalling networks in human cancer cells.
    Janssens V; Rebollo A
    Curr Mol Med; 2012 Mar; 12(3):268-87. PubMed ID: 22300139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of PP2A in viral and cellular transformation.
    Arroyo JD; Hahn WC
    Oncogene; 2005 Nov; 24(52):7746-55. PubMed ID: 16299534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein phosphatase 2A: a target for anticancer therapy.
    Perrotti D; Neviani P
    Lancet Oncol; 2013 May; 14(6):e229-38. PubMed ID: 23639323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer.
    Álvarez-Fernández M; Sanz-Flores M; Sanz-Castillo B; Salazar-Roa M; Partida D; Zapatero-Solana E; Ali HR; Manchado E; Lowe S; VanArsdale T; Shields D; Caldas C; Quintela-Fandino M; Malumbres M
    Cell Death Differ; 2018 May; 25(5):828-840. PubMed ID: 29229993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.